



Malmö 5 January 2024

**PRESS RELEASE**

## **Aptahem receives Notice of Allowance in Israel for patent family 2**

Aptahem AB (publ) announces today that the company has received a Notice of Allowance in Israel of the patent application no 273759 entitled *A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties*.

The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until, and including, 2038.

### **CEO Mikael Lindstam comments:**

"I am very pleased to receive the news that yet another country has the intention to grant the patent application for the patent family 2 and this time in Israel, a country where a lot of research and drug development are performed and is therefore a strategically important country for patent protection. This is an important increase of the value of Aptahem's development portfolio, and strengthens us from a business perspective."

### **For further information:**

Aptahem AB  
Mikael Lindstam, CEO  
Tel: +46 (0)766-33 36 99  
E-mail: [ml@aptahem.com](mailto:ml@aptahem.com)

### **About Aptahem**

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit [www.aptahem.com](http://www.aptahem.com).